

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/54, C12P 13/22, 19/02, 1/00, C12N 15/31, C07H 11/04, C12N 1/21 // C12Q 1/48, (C12N 1/21, C12R 1:07, 1:13, 1:15, 1:185, 1:19, 1:425)	A1	(11) International Publication Number: WO 98/18936 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/NL97/00582 (22) International Filing Date: 17 October 1997 (17.10.97) (30) Priority Data: 196 44 566.3 26 October 1996 (26.10.96) DE (71) Applicants (for all designated States except US): HOLLAND SWEETENER COMPANY V.O.F. [NL/NL]; Blekerij 52, NL-6212 XW Maastricht (NL). FORSCHUNGSZENTRUM JÜLICH GMBH [DE/DE]; D-52425 Jülich (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): SPRENGER, Georg [DE/DE]; Schlossstrasse 4, D-52428 Jülich (DE). SIEWE, Ruth [DE/DE]; Gebhardtstrasse 10, D-76137 Karlsruhe (DE). SAHM, Hermann [DE/DE]; Wendelinusstrasse 71, D-52428 Jülich (DE). KARUTZ, Martin [DE/NL]; Bretagnestraat 35, NL-6137 JE Sittard (NL). SONKE, Theodorus [NL/NL]; Caeciliastraat 15, NL-6143 BK Sittard (NL). (74) Agent: DAUTZENBERG, Jozef, Marie, Andreas; Octrooi- reau DSM, P.O. Box 9, NL-6160 MA Geleen (NL).	(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: MICROBIAL PREPARATION OF SUBSTANCES FROM AROMATIC METABOLISM/I		
(57) Abstract <p>The invention makes available, by means of an increased provision of intracellular metabolic intermediates, in particular of erythrose 4-phosphate, alternative processes for the microbial preparation of substances, in particular of aromatic amino acids such as L-phenylalanine, in which processes the activity of a transaldolase is increased in a microorganism producing these substances. In preferred embodiments of the invention, the activity of a transketolase or the activity of a transport protein for the PEP-independent uptake of a sugar and/or the activity of a kinase which phosphorylates the relevant sugar are/is additionally increased. The invention also relates to gene structures, and to transformed cells carrying these gene structures, which make it possible to implement these processes in a particularly successful manner.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MICROBIAL PREPARATION OF SUBSTANCES
FROM AROMATIC METABOLISM/I

5

The invention relates to a process for the microbial preparation of substances, in particular aromatic amino acids, according to Claims 1-23, 36 and 37, to gene structures according to Claims 24-29, and to transformed cells according to Claims 30-35.

Microbially prepared substances, such as fine chemicals, in particular aromatic amino acids, are of great economic interest, with the requirement for amino acids, for example, continuing to increase. Thus, L-phenylalanine, for example, is used for preparing medicaments and, in particular, also in the preparation of the sweetener aspartame (α -L-aspartyl-L-phenylalanine methyl ester). L-tryptophan is required as a medicament and as an additive to animal feeds; there is likewise a need for L-tyrosine as a medicament and also as a raw material in the pharmaceutical industry. In addition to isolation from natural materials, biotechnological preparation is a very important method for obtaining amino acids in the desired optically active form under economically justifiable conditions. Biotechnological preparation is effected either using enzymes or using microorganisms. The latter, microbial, preparation enjoys the advantage that simple and inexpensive raw materials can be employed. Since the biosynthesis of amino acids in the cell is controlled in a wide variety of ways, however, a large number of attempts have already been made to increase product formation. Thus, amino acid analogues, for example, have been employed in order to switch off the regulation of biosynthesis. For example, mutants of *Escherichia coli* permitting an increased production of L-phenylalanine were obtained by selecting for resistance to phenylalanine analogues (GB-2,053,906). A similar strategy

also led to overproducing strains of *Corynebacterium* (JP-19037/1976 and JP-39517/1978) and *Bacillus* (EP-0,138,526). Furthermore, microorganisms which have been constructed using recombinant DNA techniques are known in which the regulation of biosynthesis is likewise abolished, with the genes which encode key enzymes which are no longer subject to feedback inhibition being cloned and expressed. As a prototype, EP-0,077,196 describes a process for producing aromatic amino acids in which a 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase (DAHP synthase) which is no longer subject to feedback inhibition is overexpressed in *E. coli*. EP-0,145,156 describes an *E. coli* strain in which chorismate mutase/prephenate dehydratase are additionally overexpressed for the purpose of producing L-phenylalanine.

A feature common to the abovementioned strategies is that the intervention for improving production is restricted to the biosynthesis pathway which is specific for the aromatic amino acids. However, in order to increase production still further, efforts must be made to improve the provision of the primary metabolites, phosphoenolpyruvate (PEP) and erythrose 4-phosphate (Ery4P), which are required for producing aromatic amino acids.

PEP is an activated precursor of the glycolysis product pyruvate; Ery4P is an intermediate in the pentose phosphate pathway.

Various attempts have been made to achieve a specific improvement in the provision of the said primary metabolite Ery4P. An increased flow of carbon through the pentose phosphate pathway was achieved in *E. coli* by switching off the enzyme phosphoglucose isomerase; this resulted in tryptophan being formed (Mascarenhas D. et al., Appl. Environ. Microbiol. 57 (1991) 2995-99).

US-A-5,168,056 disclosed that overexpression of a transketolase, achieved by means of recombinant DNA techniques, makes it possible to obtain an increased provision of Ery4P and, as a consequence, an improvement in the formation of L-tryptophan, L-tyrosine or L-phenylalanine as products. Both Draths K.M. et al. (J. Am. Chem. Soc. 114 (1992) 3956-62) and Flores N. et al. (Nat. Biotechnol. 14 (1996) 620-3) demonstrated the same effect. However, as Feldmann has shown, simply increasing the activity of transketolase in *Zymomonas mobilis* strains lacking transaldolase activity leads to the enrichment of metabolites of the pentose phosphate pathway in the cells and, as a consequence, to negative effects on cell growth (Feldmann S.D. et al., Appl. Microbiol. Biotechnol. 38 (1992) 354-61). This physiological effect may possibly be attributable to an excessive intracellular concentration of sedoheptulose-7-phosphate. The inventors have also found a corresponding inhibition of biomass growth as a consequence of transketolase overexpression in the case of *E. coli* tal' strains.

The object of the invention is, therefore, to make available an alternative process for producing substances, in particular aromatic amino acids, which process is distinguished by an increased provision of intracellular metabolic intermediates for the synthesis of these substances without suffering from the above-cited disadvantages of the processes, which disadvantages are the consequence of only increasing the activity of the transketolase.

Surprisingly, this object is achieved, according to the invention, by making available a process for the microbial preparation of substances, in which process the activity of a transaldolase is increased in a micro-organism which is producing these substances, with the

activity of a phosphoenolpyruvate (PEP)-dependent sugar-uptake system in this microorganism being present, reduced or absent.

5 This result is particularly surprising in that it is in no way self-evident that transaldolases play an important role in the growth of microorganisms and in their production of substances. This particularly applies in the case of growth on hexoses. Thus, yeast strains are known, for example, which are still able to grow on
10 glucose despite having a mutation in the transaldolase gene (Schaaff L. et al., Eur. J. Biochem. 188 (1990) 597-603). Accordingly, a transaldolase should not exert any essential influence on cell growth. This is supported by the fact that bacterial species are also known which are
15 able to grow in the absence of a transaldolase (Feldmann S.D. et al., Appl. Microbiol. Biotechnol. 38 (1992) 354-62).

In addition, hexoses such as glucose, in contrast to xylose and other pentoses, can also be
20 metabolized through degradation pathways other than the pentose phosphate pathway. It is therefore in no way self-evident that transaldolase has an essential function in glucose degradation.

It may also be noted that an increased flow by way of the enzymes of the pentose phosphate pathway was
25 measured in vitro in extracts of *Saccharomyces cerevisiae* cells in which the activity of a transaldolase was increased (Senac T. et al., Appl. Environ. Microbiol. 57 (1991) 1701-6). However, the experimental conditions which
30 were selected in this study do not permit any transfer of the results to the natural phenomena of metabolic physiology which occur in living microorganisms, in particular bacteria. In addition, it may be noted that Liao J.C. et al. (Biotechn. Bioeng. 52 (1996) 129-140 have

shown that when the activities of a transaldolase and AroG are simultaneously increased, DAHP formation increases. This effect is to be ascribed mainly to the increase in AroG activity. An increase in the production of substances as a result of an increase in transaldolase activity as such is not disclosed or indicated. It is therefore in no way to be expected that there is a causal relationship between an increase in transaldolase activity in microorganisms and the provision of Ery4P for the improved production of substances. Increasing the activity (overexpression) of a transaldolase in accordance with the present invention makes available an alternative process for implementing an increased flow of carbon through the pentose phosphate pathway and consequently effecting an improved provision of the primary metabolite Ery4P. An increased quantity of Ery4P is consequently available for the microbial synthesis of substances in whose synthesis at least one intermediate of the pentose phosphate pathway, and in particular Ery4P, is involved. The inventors have shown that the improved availability of Ery4P occurs both in microorganisms in which the activity of a PEP-dependent sugar-uptake system is present or reduced and in microorganisms in which such an activity is absent. Thus, according to the invention not only organisms which still have active phosphotransferase systems (PTS) or phosphotransferase systems with reduced activity (pts⁻ strains) may be used but also organisms in which the PTS has been switched off (pts⁻ strains).

Within the meaning of the invention, substances are to be understood as being, for example, fine chemicals such as aromatic amino acids, indigo, indoleacetic acid, adipic acid, melanin, quinones and benzoic acid, and also their potential derivatives and secondary products - or, in a general manner, secondary products of intermediates

of the pentose phosphate pathway. However, this should also include all the compounds, for example pyridoxine and its derivatives, whose biochemical synthesis is promoted by the provision of erythrose 4-phosphate. Within the context of this invention, all these substances are also regarded as being substances from aromatic metabolism. It may be noted in this context that further genetic alterations to the substance-producing microorganisms are required, in addition to the novel interventions, for preparing indigo, adipic acid and other unnatural secondary products. The process according to the invention is particularly suitable for the preparation of substances in microorganisms which have not, prior to the increasing of the transaldolase activity, been selected as strains with a switched-off phosphotransferase system (pts⁻ strains) from strains which previously harboured a phosphotransferase system (pts⁺ strains). In this connection it may be noted that the non-prepublished patent specification WO-96/34961 describes such a selection from what were previously pts⁺ strains, but in this study this selection precedes the increasing of the transketolase or transaldolase activity.

With regard to increasing the activity of a transaldolase, preference is given to increasing the activity of an *Escherichia coli* transaldolase and, in particular, the activity of *Escherichia coli* transaldolase B (TalB). When the corresponding talB gene is used, this gene preferably originates from *Escherichia coli* K12 or from a strain which is derived therefrom. Besides this, however, any gene is also suitable whose gene product catalyses a reaction which corresponds to that of transaldolase, that is the conversion of sedoheptulose 7-phosphate plus glyceraldehyde 3-phosphate to Ery4P and fructose-6-phosphate.

In a particularly advantageous embodiment of the invention, the activity of a transketolase is increased in addition to increasing the activity of a transaldolase. In the presence of pentoses, the expression of a

5 transketolase gene on its own leads to a build up of metabolites in the pentose phosphate pathway (Feldmann S.D., Appl. Microbiol. Biotechnol. 38 (1992) 354-61). This has a harmful effect on the cell and results, inter alia, in the transformed cells growing at a
10 diminished rate. The inventors also observed an identical effect in the case of an *Escherichia coli* strain which was growing on glucose and which exhibited increased transketolase activity. However, simultaneously increasing the activity of a transketolase as well as that of a
15 transaldolase has now been found to be very beneficial for providing Ery4P and does not exhibit the negative side effects of a sole overexpression of a transketolase. The accumulation of metabolites of the pentose phosphate pathway which occurs when the activity of a transketolase
20 is increased consequently fails to materialize as a result of increasing the activity of a transaldolase, as the result of which the impairment in the growth of the cells is not only halted but even converted into an increase in growth. It turns out, therefore, that increasing the
25 activity of a transketolase particularly in strains having an increased activity of transaldolase in accordance with the invention is a sensible measure.

With regard to increasing the activity of a transketolase, preference is given to increasing the
30 activity of an *Escherichia coli* transketolase and, in particular, the activity of *Escherichia coli* transketolase A (TktA). When the corresponding tktA gene is used, this gene preferably originates from *Escherichia coli* K12 or from a strain which is derived therefrom. In addition to

this, however, any gene is also suitable whose gene product catalyses a reaction which corresponds to that of transketolase, that is the conversion of ribose 5-phosphate plus xylulose 5-phosphate to sedoheptulose 7-phosphate plus glyceraldehyde 3-phosphate or the conversion of xylulose 5-phosphate plus Ery4P to fructose 6-phosphate plus glyceraldehyde 3-phosphate.

In another particularly preferred embodiment of the invention, the activity of a transport protein for the PEP-independent uptake of a sugar and/or the activity of a kinase which phosphorylates the corresponding sugar is/are increased in addition to increasing the activity of a transaldolase or increasing the activity of a transaldolase and a transketolase. In the case of the transport protein, the activity of this protein is understood as being the protein-mediated uptake rate. The additional increase in the activity of one of these latter proteins, i.e. the transport protein and the kinase, or of both proteins makes it possible to achieve an even higher production of substances, in particular aromatic amino acids, due to the fact that PEP is provided in increased quantity for the condensation with Ery4P to form the primary metabolite of the general pathway for biosynthesizing aromatic compounds, i.e. deoxy-D-arabinoheptulosonate-7-phosphate (DAHP).

It is advisable to use a facilitator as the transport protein for the PEP-independent uptake of a sugar, that is a transport protein which acts in accordance with the principle of protein-mediated facilitated diffusion. In particular, it is suitable to use the glucose facilitator protein (Glfr) from *Zymomonas mobilis*. When the latter is used, the protein-encoding gene, *glfr*, is obtained, for example, from *Z. mobilis* ATCC 10988, ATCC 29191 or ATCC 31821. However, other bacterial sugar

transport genes whose gene products transport glucose, fructose or sucrose, for example, and in doing so do not use any PEP, for example the GalP system from *Escherichia coli*, are also suitable for the novel process. Genes for
5 sugar transport systems, such as HXT1 to HXT7, from eukaryotic microorganisms, such as *Saccharomyces cerevisiae*, *Pichia stipitis* or *Kluyveromyces lactis*, or sugar transport genes from other organisms in general, can also be used, provided that they can be expressed in a
10 functional manner in the microorganisms and that the gene products can, in this context, operate without using PEP for transporting the sugars. It is particularly advisable for it to be possible to express the sugar transport genes in amino acid-producing microorganisms (amino acid
15 producers).

It is particularly suitable, therefore, to use the facilitator gene *glf*, isolated from *Z. mobilis* ATCC 31821, for taking up sugars such as glucose, fructose or mannose when preparing aromatic amino acids in accordance
20 with the novel process. (Parker C. et al., Mol. Microbiol. 15 (1995) 795-802; Weisser P. et al., J. Bacteriol. 177 (1995) 3351-4). The process according to the invention is particularly suitable for the preparation of aromatic amino acids in microorganisms in which the PTS system has
25 a reduced activity or is completely absent. In such cases the PTS system may be reduced or switched off before but also after the increasing of the transaldolase activity.

The *glf* gene, in particular, should preferably be inserted at a low gene copy number in order to avoid
30 harmful effects on the cell due to excessive expression of membrane proteins. Thus, a gene copy number of from 2 to 5 is preferred, for example, for the *glf* gene. It is particularly advantageous to insert the *glf* gene into one of the genes of the *ptsHI-crr* operon, for example into the

ptsI gene.

When a sugar-phosphorylating kinase is being employed, it is advisable to use a hexose-phosphorylating kinase, preferably a kinase, in particular glucokinase (Glk), from *Zymomonas mobilis*. When the latter is used, the protein-encoding gene, *glk*, is derived, for example, from *Z. mobilis* ATCC 10988, ATCC 29191 or ATCC 31821. Other genes for hexose-phosphorylating kinases from bacteria whose gene products phosphorylate hexoses while consuming ATP, such as a fructokinase or a mannokinase, are likewise suitable for the novel process. Furthermore, genes for, for example, kinases from eukaryotic microorganisms, such as *Saccharomyces cerevisiae*, or, in a general manner, genes for sugar-phosphorylating kinases from other organisms, are also suitable, provided they can be expressed in a functional manner in the microorganisms, in particular amino acid producers, and can operate without using PEP to phosphorylate the sugars. The glucokinase gene, *glk*, for phosphorylating glucose, which gene is isolated from *Z. mobilis* ATCC 29191, is particularly suitable for preparing aromatic amino acids in accordance with the novel process.

The availability of PEP for producing the first intermediate of aromatic amino acid metabolism can be limited in microorganisms in which the flow of material towards Ery4P is increased. In these cases, it can be advantageous to reduce, or completely switch off, other PEP-consuming reactions in the metabolism, such as the reaction of the PEP:sugar phosphotransferase system (PTS), which catalyses a PEP-dependent sugar uptake, if this system is present. According to the invention, use can be made both of organisms which still possess active PTS genes (*pts*⁺ strains) and, for the further improvement of the process, of *pts* mutants in which the activity of the

pts is decreased (also to be considered as *pts*⁻ in the present case) or in which the *pts* is switched off (*pts*⁻ strains). A decrease of this nature can either be effected at the enzymic level or by using genetic methods, for example by inserting a *glf* and/or a *glk* gene into the chromosome and, in particular, into the locus of the *ptsI* gene, a procedure which simultaneously stabilizes the recombinant DNA in the chromosome (segregation stability) and consequently means that the use of a vector can be dispensed with. The inventors' experiences have shown that reducing or switching off the activity of the PTS should preferably not take place before the activity of the transaldolase is increased.

Within the meaning of the invention, measures for increasing the activity are to be understood as being all measures which are suitable for increasing the activity of the transaldolase, of the transketolase, of the transport protein, and of the kinase. The following measures are particularly suitable for this purpose:

- introduction of genes, for example using vectors or temperate phages;
- increasing the gene copy number, for example using plasmids with the aim of introducing the genes according to the invention into the microorganism at an increased copy number, that is at a copy number which is slightly (e.g. from 2 to 5 times) increased to highly (e.g. from 15 to 50 times) increased;
- increasing gene expression, for example by increasing the rate of transcription, for example by using promoter elements such as *Ptac*, *Ptet* or other regulatory nucleotide sequences, and/or by increasing the rate of translation, for example by using a consensus ribosome binding site;
- increasing the endogenous activity of enzymes which are present, for example by means of mutations which are

produced in a random manner by conventional methods, for example using UV irradiation or mutation-eliciting chemicals, or by means of mutations, such as deletion(s), insertion(s) and/or nucleotide exchange(s), which are
5 produced in a specific manner using genetic engineering methods;

- increasing the activity of enzymes by altering the structure of enzymes, for example by means of mutagenesis using physical, chemical or molecular biological or other
10 microbiological methods;

- using deregulated enzymes, for example enzymes which are no longer subject to feedback inhibition;

- introduction of corresponding genes which encode the deregulated enzymes.

15 Combinations of the abovementioned methods and other, analogous methods can also be employed for increasing the activity. The endogenous or introduced activity of transport proteins can be increased, for example, by cloning the gene using the abovementioned
20 methods, for example, or by selecting mutants which exhibit an increased transport of substrates.

Preferably, the activity is increased by integrating the gene, or the genes, into a gene structure, or into several gene structures, with each gene or the genes
25 being introduced into the gene structure as (a) single copy(ies) or at an increased copy number.

Within the meaning of the invention, a gene structure is to be understood as being a gene and any other nucleotide sequence which carries the genes according to the
30 invention. Appropriate nucleotide sequences can, for example, be plasmids, vectors, chromosomes, phages or other nucleotide sequences which are not closed circularly.

A chromosome within the meaning of the invention

is a chromosome into which at least one gene according to the invention has been inserted, with the resulting nucleic acid sequence containing at least one gene, or one gene copy, more than is naturally contained in this chromosome. On the other hand, for example, homologous recombination within a gene locus leads to a chromosome which does not necessarily have to differ from the natural form. The chromosomes which are prepared by homologous recombination are not, therefore, to be regarded as being in accordance with the invention if the natural number of homologous genes is not exceeded.

Within the meaning of the invention, a gene structure is also to be understood as being a combination of the abovementioned gene carriers, such as vectors, chromosomes and temperate phages, on which the genes according to the invention are distributed. For example, two *tal* genes can be introduced into the cell on a vector or two *tal* genes can be inserted into a chromosome. In addition, a further gene can, for example, be introduced into the cell using a phage. The same applies to the other genes according to the invention. These examples are not intended to exclude other combinations of gene distributions from the invention. In any case, it is crucial that the number of genes contained in the microorganism according to the invention exceeds the natural number of the corresponding genes. Preferably, the number of *glf* genes, for example, will be increased by a factor of from 2 to 5 in order to achieve the increase in activity according to the invention. No cell-toxic effect will appear at these concentrations. However, it is also conceivable to introduce the genes according to the invention into the microorganism at a higher copy number of up to 50 gene copies of a form having the same effect.

In the novel process for producing substances,

preference is given to employing microorganisms in which one or more enzymes which are additionally involved in synthesizing the substances are deregulated and/or have an increased activity.

5 These enzymes are, in particular, the enzymes of aromatic amino acid metabolism and, especially, DAHP synthase, shikimate kinase and chorismate mutase/prephenate dehydratase, and also all the other enzymes which are involved in synthesizing intermediates
10 of aromatic metabolism and their secondary products.

Apart from the enzymes according to the invention, the deregulation and overexpression of DAHP synthase in particular is of importance for preparing substances such as adipic acid, bile acid and quinone
15 compounds and their derivatives. In addition, shikimate kinase should be deregulated, and its activity increased, in order to achieve superelevated synthesis of, for example, tryptophan, tyrosine, indigo and derivatives of hydroxybenzoic acid and aminobenzoic acid and naphtho-
20 quinones and anthroquinones and also their secondary products. Deregulated and overexpressed chorismate mutase/prephenate dehydratase is additionally of particular importance for efficiently producing phenylalanine and phenylpyruvic acid and their derivatives. However,
25 this is also intended to encompass all the other enzymes whose activities contribute to the biochemical synthesis of substances, that is compounds whose production is promoted by the provision of erythrose 4-phosphate, for example pyridoxine and its derivatives. It may be noted
30 that further genetic alterations to the substance-producing microorganisms, in addition to the novel interventions, are required for the purpose of preparing indigo, adipic acid and other unnatural secondary products.

The novel process is suitable, in particular, for preparing aromatic amino acids, in particular phenylalanine. In the latter case, the gene expression and/or the enzyme activity of a deregulated DAHP synthase (e.g. in *E. coli* AroF or AroH) and/or of a likewise deregulated chorismate mutase/prephenate dehydratase (PheA) is preferably increased.

Escherichia species, and also microorganisms of the genera *Serratia*, *Bacillus*, *Corynebacterium* or *Brevibacterium*, and other strains which are known from conventional amino acid methods, are suitable for use as production organisms. *Escherichia coli* is particularly suitable.

Another object of the invention is to provide suitable gene structures, and transformed cells carrying these gene structures, which enable the process to be implemented in a particularly successful manner. Within the context of the invention, novel gene structures are now made available, which gene structures contain, in recombinant form, a) a gene encoding a transaldolase or a gene encoding a transaldolase and a gene encoding a transketolase, and b) at least one gene encoding a transport protein for the PEP-independent uptake of a sugar or encoding a kinase which phosphorylates a sugar. In these gene structures, it is preferred that the gene for the transport protein encode a facilitator and the gene for the kinase encode a hexose-phosphorylating kinase. In particular, the genes for the transaldolase and the transketolase are derived from *Escherichia coli* and the genes for the transport protein and the kinase are derived from *Zymomonas mobilis*.

Gene structures are particularly advantageous in which the gene for the transaldolase is *Escherichia coli* talB and the gene for the transketolase is *Escherichia*

coli tktA, while the gene for the transport protein is *Zymomonas mobilis glf* and the gene for the kinase is *Zymomonas mobilis glk*.

The appropriate genes are isolated, and the
5 cells are transformed, in accordance with current methods:
the complete nucleotide sequences of the *talB* and *tktA*
genes from *Escherichia coli* K12 are known (Yura T. et al.,
Nucl. Acid Res. 20 (1992) 3305-8; Sprenger G.A., Biochim.
Biophys. Acta 1216 (1993) 307-10; Sprenger G.A. et al., J.
10 Bacteriol. 177 (1995) 5930-9) and deposited in databases
such as that of the EMBL in Heidelberg. When the
Escherichia coli talB gene is being cloned, the polymerase
chain reaction (PCR) method is suitable, for example, for
specifically amplifying the gene using chromosomal DNA
15 from *Escherichia coli* K12 strains (Sprenger G.A. et al.,
J. Bacteriol. 177 (1995) 5930-9). The homologous
complementation of a transketolase-deficient mutant is
suitable, for example, when cloning the *Escherichia coli*
tktA gene (Sprenger G.A. in: Bisswanger H. et al.,
20 Biochemistry and physiology of thiamine diphosphate
enzymes, VCH (1991) 322-6).

When cloning the *Zymomonas mobilis* transport
gene *glf* or the *Zymomonas mobilis* glucokinase gene *glk*,
for example, PCR, for example, is suitable for
25 specifically amplifying the gene using chromosomal DNA
from *Zymomonas mobilis* strains ATCC 29191 or ATCC 31821,
as is also the heterologous complementation of *Escherichia*
coli mutants which are defective in PTS functions and
which are therefore unable to transport glucose, for
30 example (Snoep J.L. et al., J. Bacteriol. 174 (1994) 1707-
8; Parker C. et al., Mol. Microbiol. 15 (1995) 795-82;
Weisser P. et al., J. Bacteriol. 177 (1995) 3351-4). After
isolating the genes and recombining them in vitro with
known low copy number vectors such as pACYC184, pACYC177,

pSC101 or pZY507 (Weisser P. et al., J. Bacteriol. 177 (1995) 3351-4), the host cell is transformed using chemical methods, electroporation, conjugation or transduction.

5 The isolated transaldolase gene can be integrated, together with one or more of the genes described within the context of the invention, in any combination, into a gene structure or into several gene structures. Without considering the precise allocation to
10 gene structures, this leads to combinations such as talB, talB + tktA, talB + glf, talB + glk, talB + glf + glk, talB + tktA + glf, talB + tktA + glk or talB + tktA + glf + glk.

 Gene structures are advantageous which contain
15 at least one regulatory gene sequence which is assigned to one of the genes. Thus, reinforcement of regulatory elements can preferably be effected at the level of transcription by, in particular, reinforcing the transcription signals. This can be effected, for example,
20 by increasing the activity of the promoter or the promoters by altering the promoter sequences which are located upstream of the structural genes or by completely replacing the promoters with more effective promoters. Transcription can also be reinforced by exerting an
25 appropriate influence on a regulatory gene which is assigned to the genes; in addition to this, however, it is also possible to reinforce translation by, for example, improving the stability of the messenger RNA (mRNA).

 The most suitable gene structures are those in
30 which at least one of the described genes is incorporated such that it is under the control of an inducible promoter. When the genes are arranged on a gene structure according to the invention, a promoter can be located upstream of a gene or be located, as a common promoter,

upstream of several genes, or use can be made of two opposed promoters between which the genes are arranged such that they are read off in opposite directions. In this context, the *glf* gene, for example, can be located downstream of a relatively weak promoter (e.g. *Ptet*) and other genes can be under the control of the *tac* promoter. One or more DNA sequences can be located upstream and/or downstream of the genes contained in a gene structure, with or without an upstream promoter or with or without an assigned regulatory gene. By means of using inducible promoter elements, e.g. *lacI^q/Ptac*, it is possible to switch on new functions (induction of enzyme synthesis), for example by adding chemical inducers such as isopropylthiogalactoside (IPTG).

The object of the invention is also achieved by providing transformed cells which harbour a gene structure according to the invention in replicable form.

Within the meaning of the invention, a transformed cell is to be understood as being any microorganism which carries a gene structure according to the invention, which gene structure brings about the increased formation of substances in the cell. The host cells can be transformed by means of chemical methods (Hanahan D., J. Mol. Biol. 166 (1983) 557-580) and also by means of electroporation, conjugation or transduction.

For the transformation, it is advantageous to employ host cells in which one or more enzymes which are additionally involved in the synthesis of the substances are deregulated and/or have an increased activity. A microorganism strain, in particular *Escherichia coli*, which is producing an aromatic amino acid or another substance according to the invention is transformed with the gene structure which contains the relevant genes. For transforming with the gene structures, it is advantageous

to employ host cells in which the activity of the PEP-dependent sugar uptake system, if present, is decreased or switched off.

5 In particular, transformed cells are provided which are able to produce an aromatic amino acid, with the aromatic amino acid preferably being L-phenylalanine.

Using the novel process, and the microorganism which has been transformed in accordance with the teaching of the invention, a broad spectrum of substrates can be
10 employed for producing substances. Within the context of the invention, a process for the microbial preparation of substances is consequently also provided in which cells which have been transformed in accordance with the invention and in which a gene structure is present which
15 contains at least one regulatory gene sequence which is assigned to one of the genes are cultured, with enzyme synthesis being induced in the microorganisms after at least 2 cell divisions (beginning of the exponential growth phase). Consequently, the production of the micro-
20 organisms can be increased independently of their growth.

In a particularly preferred embodiment of the novel process, transformed cells are employed which, in addition to the intermediates of the pentose phosphate pathway, also contain an increased availability of other
25 metabolites of central metabolism. These metabolites include, for example, pyruvate from glycolysis or gluconeogenesis, or oxaloacetate from the citric acid cycle. Furthermore, the relevant compound, or its precursors, that is the precursors of pyruvate or of
30 metabolites of the citric acid cycle, such as fumarate or malate, can be made available to the growing cells by feeding.

The invention is explained in more detail below with the aid of a few implementation examples. The

following strains have been deposited at DSM under the terms of the Budapest treaty:

- DSM 11210 *Escherichia coli* AT2471/pZYTT7tal
5 DSM 11209 *Escherichia coli* AT2471/pZY557tkttal
DSM 11206 *Escherichia coli* AT2471GP704glfint PTS⁻
DSM 11205 *Escherichia coli* AT2471glfint PTS⁻

10 The host organism employed, i.e. AT2471, has been deposited by Taylor and Trotter (Bacteriol. Rev. 13 (1967) 332-353) in the CGSC under number 4510 and is freely accessible.

The characteristics and the provenance of all the microorganisms employed within the context of this
15 patent application are described in detail in Table 1.

The text which follows is intended to indicate the materials and methods employed and to support the invention with experimental examples and comparative
examples:

20

General methods

In the genetic studies, strains of *E. coli* were, unless otherwise indicated, cultured on LB medium consisting of Difco bacto-tryptone ($10 \text{ g} \cdot \text{l}^{-1}$), Difco yeast
25 extract ($5 \text{ g} \cdot \text{l}^{-1}$) and NaCl ($10 \text{ g} \cdot \text{l}^{-1}$). Depending on the resistance properties of the strains employed, carbenicillin ($20\text{-}100 \text{ mg} \cdot \text{l}^{-1}$) and/or chloramphenicol ($17\text{-}34 \text{ mg} \cdot \text{l}^{-1}$) was/were added to the medium if necessary. For this, carbenicillin was first of all dissolved in water, and
30 chloramphenicol in ethanol, and the solutions were added, after having been sterilized by filtration, to the previously autoclaved medium. Difco bacto-agar (1.5%) was added to the LB medium for preparing agar plates. Plasmid DNA was isolated from *E. coli* by means of alkaline

lysis using a commercially available system (Quiagen, Hilden). Chromosomal DNA was isolated from *E. coli* and *Z. mobilis* as described by Chen and Kuo (Nucl. Acid Res. 21 (1993) 2260).

5 Restriction enzymes, DNA polymerase I, alkaline phosphatase, RNase and T4 DNA ligase were used in accordance with the producers' instructions (Boehringer, Mannheim, Germany or Promega, Heidelberg, Germany). For restriction analysis, the DNA fragments were fractionated
10 in agarose gels (0.8%) and isolated from the agarose by means of extraction using a commercially available system (Jetsorb Genomed, Bad Oeynhausen, Germany).

 For Southern analyses, chromosomal DNA (10 µg) was digested with restriction enzymes, size-fractionated
15 by gel electrophoresis and transferred to a nylon membrane (Nytran 13, Schleicher and Schuell, Dassel, Germany) by means of vacuum-mediated diffusion (VacuGene System, Pharmacia, Freiburg, Germany). Appropriate DNA fragments were isolated, labelled with digoxigenin-dUTP and used as
20 probes. Labelling, hybridization, washing procedures and detection were performed with the aid of a commercially available labelling and detection system (Boehringer, Mannheim, Germany).

 For transformation, the cells were incubated at
25 37°C and 200 rpm for 2.5-3 h in LB medium (5 ml tubes). At an optical density (620 nm) of approx. 0.4, the cells were centrifuged down and taken up in one tenth the volume of TSS (LB medium containing 10% (w/v) PEG 8000, 5% (v/v) DMSO and 50 mM MgCl₂). After a 30-minute incubation at 4°C
30 with from 0.1 to 100 ng of DNA, and subsequent incubation at 37°C for 1 h, the cells were plated out on LB medium containing an appropriate antibiotic.

Example 1

Preparation of pZY557tal, pBM20tal and pZY557tkktal as prototypes of plasmid-based gene structures according to the invention, and of pZY557tkt

Plasmid pZY507 (Weisser et al. 1995 J. Bacteriol 177: 3351-3345) was opened using the restriction enzymes *Bam*HI and *Hind*III and the larger fragment (10.1 kB of DNA) was isolated. A part of the multiple cloning site was excised from vector pUCBM20 (Boehringer, Mannheim, Germany) using *Bam*HI and *Hind*III and ligated to the large pZY507*Bam*HI/*Hind*III fragment, resulting in vector pZY557, which is similar to vector pZY507 apart from the other restriction cleavage sites. The *talB* gene was amplified from vector pGSJ451 (Sprenger G.A. et al., J. Bacteriol. 177 (1995) 5930-36) by means of PCR. For this, use was made of oligonucleotide I:

5' CCGCATGCTGTTTAAAGAGAAATA 3' (the base pairs which are underlined here correspond to base pairs 84 to 101 of the *talB* sequence from Sprenger G.A. et al., J. Bacteriol. 177 (1995) 5930-6), which was provided with a cleavage site for the restriction enzyme *Sph*I, and of the commercially obtainable M13/pUC sequencing primer (No. 1010093, Boehringer Mannheim, Germany) as oligonucleotide II. The resulting amplified DNA fragment contains a cleavage site for *Sph*I at each end and was cleaved with the restriction enzyme *Sph*I. This fragment was then ligated to vectors pZY557 and pUCBM20, respectively, which vectors had also been linearized with *Sph*I. The recombinant plasmids pZY557tal and pBM20tal, respectively, were obtained after transforming *E. coli* with the two ligation solutions and cloning the transformants. The *tktA* gene was amplified by PCR from the vector pGSJ427 (Sprenger G.A. et al., Eur. J. Biochem. 230 (1995) 525-32) with a cleavage site for the restriction enzyme *Not*I being inserted at the 5' end and a cleavage site for the enzyme *Sph*I being inserted at the 3'

end. Use was made in this case of oligonucleotides III:
5' TTAGCGGCCGCCCTTCATCATCCGATCT 3' (the base pairs which
are underlined here correspond to base pairs 126 to 146 of
the *tktA* sequence from Sprenger G.A., Biochim. Biophys.

5 Acta. 1216 (1993) 307-10), which was provided with a
cleavage site for the restriction enzyme *NotI*, and IV: 5'

ATAGCATGCTAATTACAGCAGTTC 3' (the base pairs which are
underlined here correspond to base pairs 2018 to 2036 of
the *tktA* sequence from Sprenger G.A., Biochim. Biophys.

10 Acta. 1216 (1993) 307-10), which was provided with a
cleavage site for *SphI*. The resulting PCR fragment was
cleaved with *NotI* and *SphI* and ligated into vector
pZY557tkt, which had been treated in the same way,

15 resulting in vector pZY557tkt. pZY557tkt was then opened
with *SphI* and ligated to the *SphI*-cleaved PCR fragment
containing *talB*. After transforming *E. coli* and cloning
the transformants (see above), plasmids were obtained
which contained the *tktA* gene and the *talB* gene oriented
in the same direction downstream of the *tac* promoter and
20 which were subsequently used as gene structure
pZY557tkktal.

The resulting transformants were stored at -80°C
on LB medium in the form of glycerol cultures (30%). When
needed, the glycerol cultures were thawed directly before
25 use.

Example 2

Effect of the increased activity of a transaldolase on the
growth of strains in which transketolase activity is also
30 increased

The growth of the *E. coli* strains AT2471,
AT2471/pZY557tkt, AT2471/pZT557tal and AT2471/pZY557tkktal
on glucose was investigated in mineral medium. This con-
sisted of Na citrate·3H₂O (1.0 g·l⁻¹), MgSO₄·7H₂O (0.3 g·l⁻¹

¹), KH_2PO_4 ($3.0 \text{ g} \cdot \text{l}^{-1}$), K_2HPO_4 ($12.0 \text{ g} \cdot \text{l}^{-1}$), NaCl ($0.1 \text{ g} \cdot \text{l}^{-1}$), $(\text{NH}_4)_2\text{SO}_4$ ($5.0 \text{ g} \cdot \text{l}^{-1}$), $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ ($15.0 \text{ mg} \cdot \text{l}^{-1}$), $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ($0.75 \text{ g} \cdot \text{l}^{-1}$) and L-tyrosine ($0.04 \text{ g} \cdot \text{l}^{-1}$). Additional minerals were added in the form of a trace element solution ($1 \text{ ml} \cdot \text{l}^{-1}$), which was composed of $\text{Al}_2(\text{SO}_4)_3 \cdot 18\text{H}_2\text{O}$ ($2.0 \text{ g} \cdot \text{l}^{-1}$), $\text{CoSO}_4 \cdot 6\text{H}_2\text{O}$ ($0.7 \text{ g} \cdot \text{l}^{-1}$), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ($2.5 \text{ g} \cdot \text{l}^{-1}$), H_3BO_3 ($0.5 \text{ g} \cdot \text{l}^{-1}$), $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ ($20.0 \text{ g} \cdot \text{l}^{-1}$), $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ ($3.0 \text{ g} \cdot \text{l}^{-1}$), $\text{NiSO}_4 \cdot 3\text{H}_2\text{O}$ ($2.0 \text{ g} \cdot \text{l}^{-1}$) and $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ($15.0 \text{ g} \cdot \text{l}^{-1}$). Vitamin B1 ($5.0 \text{ mg} \cdot \text{l}^{-1}$) was dissolved in water and added, after having been sterilized by filtration, to the medium after the latter had been autoclaved, as were carbenicillin and/or carbenicillin and chloramphenicol as the need arose. Glucose ($30 \text{ g} \cdot \text{l}^{-1}$) was autoclaved separately and likewise added to the medium after the latter had been autoclaved.

For the experiments, shaking flasks (1000 ml containing 100 ml of mineral medium) were inoculated with 2 ml of glycerol culture and incubated at 37°C and 150 rpm for 72 h on an orbital shaker. After reaching an optical density (620 nm) of ≈ 1 , the cells were induced by adding 15-100 μM IPTG. The optical density of the culture was measured at regular intervals up to this point. Under the above-described conditions, the host organism *E. coli* AT2471 reached an optical density of 1.2 after 7.25 h. The increase in the activity of the transketolase in mutant AT2471/pZY557tkl led to a marked reduction in the rate of growth; while having an identical optical density at the beginning of the experiment, this strain only reached an optical density of 0.49 after 7.25 h. The growth-inhibiting effect is probably attributable to the synthesis of inhibitory concentrations of metabolic intermediates of the pentose phosphate pathway.

The increase in the activity of the transaldolase in mutant AT2471/pZY557tal also led to a

marked reduction (almost as marked as in the case of the transketolase) in the growth rate; an optical density of 0.52 was reached after 7.25 h. It was possible to reach an optical density of 1.1 after 7.25 h by increasing the activity of the transaldolase in addition to that of the transketolase, as was effected in *E. coli* AT2471/pZY557tkttal. This result makes it clear that additionally increasing the activity of a transaldolase in a strain having an increased activity of transketolase cancels the negative effects of only increasing the activity of the transketolase and permits virtually uninhibited growth.

Example 3

15 Determination of the enzyme activities of the transaldolase

In order to determine the activity of the transaldolase, the cells of *E. coli* AT2471, AT2471/pZY507, AT2471/pZY557tal and AT2471/pZY557tkttal were cultured as described above with, however, 3-(morpholino)propane-sulphonic acid (MOPS, $16.7 \text{ g} \cdot \text{l}^{-1}$) being added to the medium and the phosphate concentration being lowered to one tenth of the concentration which was employed in the growth experiments. In order to check the induction of the cells, parallel experimental mixtures were set up, one of which mixtures was induced by adding IPTG ($20 \mu\text{M}$) after 7 cell divisions ($\text{OD} \approx 1$). 20 ml of culture broth were removed from all the mixtures directly before adding the inducer to the relevant flasks and 3 h after the time of induction and the cells were sedimented at 6000 g for 10 min at 4°C .

The harvested cells were washed in 50 mM glycylglycine buffer, pH 8.5, containing 1 mM dithiothreitol, 10 mM MgCl_2 , and 0.5 mM thiamine

diphosphate. The cells in the sediment were disrupted by ultrasonic treatment (Branson 250 Sonifier fitted with a microtip) in a sonication cycle of 25% and at an intensity of 40 watts for 4 min per ml of cell suspension. After centrifuging at 18,000 g for 30 min at 4°C, the supernatant (crude extract) was used for measuring the activity of the transaldolase.

The transaldolase activity in the crude extract was determined using an enzymic test which was optically coupled to the formation of NAD. For this, the crude extract was incubated in a total volume of 1 ml containing 0.8 mM fructose 6-phosphate, 4 mM erythrose 4-phosphate and 0.3 mM NADH in buffer (50 mM glycylglycine, pH 8.5, 1 mM dithiothreitol, 10 mM MgCl₂ and 0.5 mM thiamine diphosphate). The resulting glyceraldehyde 3-phosphate was reacted with the enzymes triosephosphate isomerase (9 U) and glycerol 3-phosphate dehydrogenase (3 U), which enzymes were also added, with the formation of NAD. The oxidation of NADH was monitored spectrophotometrically at 340 nm ($\epsilon = 6.3 \cdot 10^3 \text{ l} \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}$), with the conversion of 1 μmol of NADH being equivalent to the consumption of 1 μmol of fructose 6-phosphate. The turnover of 1 μmol of NADH per min was defined as 1 U.

The protein concentration in crude extracts was determined as described by Bradford (Anal. Biochem. 72 (1976) 248-254) using a commercially available colour reagent. Bovine serum albumin was used as the standard.

Table 2 shows the results of the enzyme measurements when using the host strain *E. coli* AT2471 and its mutants which harbour one of the plasmids pZY557, pZY557tal or pZY557tkttal. At the time of induction, the host strain and the strain carrying the vector pZY557 were found to have a transketolase activity of about $0.65 \text{ U} \cdot (\text{mg of protein})^{-1}$. As shown for *E. coli* AT2471/pZY557, this

value increased in three hours, as the result of physiological growth, to $0.8 \text{ U} \cdot (\text{mg of protein})^{-1}$. Due to the absence of the *tal* gene on the vector employed, it was not to be expected that the induction which was performed in this experiment would have any effect.

In parallel experimental mixtures, *E. coli* AT2471/pZY557*tal* was found to have transketolase activities of 0.53 and $0.61 \text{ U} \cdot (\text{mg of protein})^{-1}$, respectively, at the time of induction. While the value for the transaldolase activity increased in 3 h to only $0.6 \text{ U} \cdot (\text{mg of protein})^{-1}$ when the culture was not induced, the transaldolase activity achieved a value of $1.06 \text{ U} \cdot (\text{mg of protein})^{-1}$ as a result of induction. In other experimental mixtures, *E. coli* AT2471/pZY557*tkktal* was used in what were otherwise identical experiments; in this case, the transaldolase activity had increased in the first 3 h after inducing the cells from 0.8 to $1.16 \text{ U} \cdot (\text{mg of protein})^{-1}$, which corresponded to a doubling of the activity as compared with the corresponding experiments using the host strain.

Example 4

Production of substances using strains which exhibit an increased transketolase activity in addition to the increased transaldolase activity

The medium which was employed for the growth experiments was used for determining synthetic performance. The cultures of *E. coli* AT2471 and AT2471/pZY557*tkktal* were induced at an optical density of 1 and the period of culture was extended to 72 h. After 24 and 48 h, the pH of the cultures was measured and brought back to the starting value of 7.2, if required, by adding KOH (45%). In addition, samples (2 ml) were taken after 24, 48 and 72 h for determining the optical density as

well as the concentrations of glucose and L-phenylalanine.

The phenylalanine concentration was determined by means of high pressure liquid chromatography (HPLC, Hewlett Packard, Munich, Germany) in combination with
5 fluorescence detection (extinction 335 nm, emission 570 nm). A Nucleosil-120-8-C18 column (250 · 4.6 mm) was used as the solid phase; the column was eluted using a gradient (eluent A: 90% 50 mM phosphoric acid, 10%
10 methanol, pH 2.5; eluent B: 20% 50 mM phosphoric acid, 80% methanol, pH 2.5; gradient: 0-8 min 100% A, 8-13 min 0% A, 13-19 min 100% A). The elution rate was set at 1.0 ml·min⁻¹; the column temperature was set at 40°C. Post-column derivatization was carried out using
15 o-phthalic dialdehyde in a reaction capillary (14 m · 0.35 mm) at room temperature. L-phenylalanine was found to have a retention time of 6.7 min under the conditions described.

Measurement of the glucose concentration with enzyme test strips (Diabur, Boehringer Mannheim, Germany)
20 and, depending on the results, the subsequent addition of 2 ml of a concentrated glucose solution (500 g·l⁻¹) ensured that glucose limitation did not arise in the experimental mixtures. After an incubation time of 48 h, a (phenylalanine) index value of 119 was achieved after
25 inducing the host strain *E. coli* AT2471; this compares with a phenylalanine value of 100 for the uninduced host strain. Simply introducing the plasmid pZY557tkttal into the host strain had the result of increasing this index value, describing the phenylalanine concentration, to 167
30 even without inducing the cells. As the experiments show, inducing the strain *E. coli* AT2471/pZY557tkttal resulted in a further increase to a value of 204. This corresponded to an increase of 71% as compared with the induced host strain.

This result demonstrates the positive effect according to the invention, which effect increases the synthesis of aromatic compounds, of additionally increasing the activity of a transketolase in strains which already have an increased transaldolase activity, or of additionally increasing the activity of the transaldolase in strains which already have an increased transketolase activity.

10 Example 5

Production of substances using strains having an increased transaldolase activity

The mutant *E. coli* AT2471/pZY557tal was cultured in an experiment which was otherwise identical to that described in Example 4. After 48 h, induction of the strain resulted in a (phenylalanine) index value of 131, which compares with a phenylalanine value of 100 for the uninduced strain.

This result clearly demonstrates the positive effect which increasing the activity of a transaldolase exerts on the synthesis of aromatic substances, particularly after inducing in accordance with the invention.

25 Example 6

Production of substances using PTS⁻ mutants in which a PEP-independent sugar uptake system is being expressed in addition to there being an increased transaldolase activity, with the transaldolase activity being increased after the introduction of the PEP-independent sugar-uptake system.

The *glf* gene was obtained, as described by Weisser P. et al. (J. Bacteriol. 177 (1995) 3351-54) using PCR (Mullis K.B. et al., Meth. Enzymol. 155 (1987) 335-

50). The complete nucleotide sequence of this gene is available (Barnell W.O. et al., J. Bacteriol. 172 (1990) 7227-40). The *glf* gene was amplified using plasmid pZY600 as the template (Weisser P. et al., J. Bacteriol 177
5 (1995) 3351-4).

For the purpose of integrating the *glf* gene into genes which encode components of the *E. coli* PTS system, plasmid pPTS1 (see Table 1) was digested with *Bgl*II and treated with Klenow fragment. The unique cleavage site is
10 located in the *ptsI* gene. The *glf* gene was isolated, as a *Bam*HI-*Kpn*I fragment, from plasmid pBM20*glf*glk and likewise treated with Klenow fragment. Clones carrying the *glf* in the same orientation as the *ptsHI* genes were obtained by blunt-end ligation. A 4.6 kb *Pst*I fragment carrying the 3'
15 region of the *ptsH* gene and *ptsI* containing integrated *glf* and *crr* was obtained from the resulting plasmid pPTS*glf*. This fragment was ligated into the *Eco*RV cleavage site of vector pGP704. Since this vector is only able to replicate in λ *pir* strains, the vector has been integrated into the
20 chromosome by transformants which do not harbour this phage if these transformants are able to grow on carbenicillin. The integration was checked by Southern blot analysis (Miller V.L. et al., J. Bacteriol. 170 (1988) 2575-83). The resulting transformants contained the
25 complete PTS genes in addition to the *glf* gene.

The vector moiety can be recombined out in a second homologous crossover, resulting in the loss of the carbenicillin resistance. Since, in this case, the *pts* genes are interrupted by the insertion of the *glf* gene,
30 the PTS is not expressed in a functional manner in these mutants. The desired PTS⁻ mutants were selected as follows: after subculturing the transformants, which were still PTS⁺, several times on LB medium without antibiotics, aliquots of the cell suspension were plated

out on LB plates containing $100 \mu\text{g}\cdot\text{l}^{-1}$ phosphomycin. PTS⁻ mutants are able to grow on these plates. Growing clones were streaked out on LB plates containing either phosphomycin or $20 \mu\text{g}\cdot\text{l}^{-1}$ carbenicillin. Chromosomal DNA was
5 isolated from clones which still exhibited growth on the phosphomycin plates but which were not able to grow on the carbenicillin plates. The integration of the *glf* gene into the genes which encode the PTS system was confirmed by Southern analysis. Corresponding mutants were identified
10 as being phenotypically PTS-deficient. One clone was selected as the host organism *E. coli* AT2471glfintPTS⁻ and used for the transformations (see above) with plasmid pZY557tal. Following the experimental conditions described for Examples 4 and 5, the PTS-negative mutant *E. coli*
15 AT2471glfintPTS⁻/pZY557tal, and the corresponding host strain AT2471glfintPTS⁻, were in each case cultured in two parallel mixtures and the cells of one mixture in each case were induced after approx. 7 divisions.

The induction reduced the synthetic performance
20 of the host strain, which initially had an index value of 100 without induction, down to a value of 56. By comparison, the induction increased the phenylalanine index value from 73 to 103, and consequently above the initial value for the host strain, in cultures of the
25 transformed strain AT2471glfintPTS⁻/pZY557tal.

This result demonstrates that simply increasing the transaldolase activity has a positive effect on the synthesis of phenylalanine even in those microorganisms in which the activity of the PTS system is diminished, or
30 this system is completely switched off, and into which, at the same time, a PEP-independent sugar uptake system has been integrated.

Example 7

Production of substances using PTS⁻ mutants in which in addition to an increased transaldolase activity a PEP-independent sugar-uptake system has been expressed, with the transaldolase activity being increased before the introduction of the PEP-independent sugar-uptake system.

E. coli AT2471/pZY557tal was obtained as described in Example 1. Subsequently in this strain a *glf* gene was integrated into the genes which encode components of the PTS system of *E. coli*. This integration was carried out as described in Example 6. Using the experimental conditions described in Examples 4 and 5, these PTS-negative *E. coli* AT2471*glf*intPTS⁻/pZY557tal mutants were cultured. It was found that the biosynthetic performance of the derived mutants corresponded to that of the strains described in Example 6.

Example 8

Production of substances in a fermentation vessel using strains having an increased transaldolase activity and strains having an increased transketolase activity in addition to their increased transaldolase activity.

The mutants *E. coli* AT2471, *E. coli* AT2471/pZY557tal and *E. coli* AT2471/pZY557tkttal were cultured in a fermentation vessel (reactor volume 15 l). To this end, two shaking flasks (2000 ml) with the mineral medium described in Example 2 (250 ml) were used for preculturing. In this process, the glucose concentration was reduced to 5.0 g.l⁻¹. The flasks were inoculated with 2 ml of glycerol culture and incubated on an orbital shaker at 37°C and 150 rpm until an optical density (600 nm) of 3 was reached.

The precultures were used for inoculating 4.5 l of production medium. This contained MgSO₄·7H₂O (0.3 g.l⁻¹), KH₂PO₄ (3.0 g.l⁻¹), NaCl 0.1 (g.l⁻¹), (NH₄)₂SO₄ (5.0 g.l⁻¹).

¹), $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ ($15.0 \text{ mg} \cdot \text{l}^{-1}$), $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ($0.75 \text{ g} \cdot \text{l}^{-1}$) and L-tyrosine ($0.24 \text{ g} \cdot \text{l}^{-1}$). Additional minerals were added in the form of a trace element solution ($1.5 \text{ ml} \cdot \text{l}^{-1}$), which was composed of $\text{Al}_2(\text{SO}_4)_3 \cdot 18\text{H}_2\text{O}$ ($2.0 \text{ g} \cdot \text{l}^{-1}$), $\text{CoSO}_4 \cdot 6\text{H}_2\text{O}$ ($0.7 \text{ g} \cdot \text{l}^{-1}$), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ($2.5 \text{ g} \cdot \text{l}^{-1}$), H_3BO_3 ($0.5 \text{ g} \cdot \text{l}^{-1}$), $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ ($20.0 \text{ g} \cdot \text{l}^{-1}$), $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ ($3.0 \text{ g} \cdot \text{l}^{-1}$), $\text{NiSO}_4 \cdot 3\text{H}_2\text{O}$ ($2.0 \text{ g} \cdot \text{l}^{-1}$) and $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ($15.0 \text{ g} \cdot \text{l}^{-1}$). Vitamin B1 ($75.0 \text{ mg} \cdot \text{l}^{-1}$) was dissolved in water and added, after having been sterilized by filtration, to the medium after the latter had been autoclaved. Glucose ($15 \text{ g} \cdot \text{l}^{-1}$) was autoclaved separately and likewise added to the medium after the latter had been autoclaved. By adding NH_4OH (25%) the pH value in the medium was controlled at 7, the oxygen partial pressure being controlled at a value of 20% via the stirrer speed, the air volume fed and the pressure inside the fermentation vessel. By adding a glucose solution ($700 \text{ g} \cdot \text{l}^{-1}$) the glucose concentration in the culture medium was kept at values around $5 \text{ g} \cdot \text{l}^{-1}$. Depending on the fermentation time, L-tyrosine was added to the glucose solution in variable concentrations in order to avoid L-tyrosine limitation.

In experiments in which cell induction was effected, this was done in accordance with the invention after 6 hours by adding $50 \mu\text{M}$ of IPTG. After an incubation time of 36 hours, a (phenylalanine) index value of 120 was achieved by simply introducing the pZY557tal plasmid; this compares with a (phenylalanine) index value of 100 for the uninduced host strain *E. coli* AT2471. By means of induction according to the invention this value could be raised further to 153. By introducing the pZY557tkttal plasmid alone and thus raising the transketolase activity in addition to the transaldolase activity, a (phenylalanine) index value of 130 could be achieved compared with the host strain. The experiments further

showed that the induction of the strain *E. coli* AT2471/pZY557kttal enabled a further increase in the (phenylalanine) index value to 250. This corresponds to an increase of 92% compared with the uninduced strain.

- 5 This result shows that even in experiments carried out in fermentation vessels an increase in the synthesis of aromatic compounds can be achieved according to the invention by increasing the transaldolase activity as well as by increasing the transketolase activity in
- 10 strains which already have an increased transaldolase activity.

Table 1:

	Strains and plasmids	Genotype/ characteristics	Source or reference
5	<i>E. coli</i> AT2471	<i>tyrA4, relA1, spoT1, thi-1</i>	Taylor and Trotter, Bacteriol. Rev. 13 (1967) 332-53
	<i>E. coli</i> SY327	<i>araD, Δ(lac-pro), Rif^r, recA56, λ-phage pir function</i>	Miller et al., J. Bacteriol. 170 (1988) 2575-83
	<i>E. coli</i> CC118	<i>Δ(ara-leu), araD, ΔlacX74, galE, galK, phoA20, thi-1, rpsE, rpoB, argE (Am), recA1, λpir lysogen</i>	Manoil et al., Proc. Natl. Acad. Sci USA 82 (1985) 8129-33
10	pZY507	Cm ^r	Weisser et al., J. Bacteriol 177 (1995) 3351-4
	pZY507glfglk	<i>Z. mobilis glf and glk genes in p-ZY507</i>	Weisser et al., J. Bacteriol 177 (1995) 3351-4
	pZY557	pZY507, multiple cloning site of pUCBM20, Cm ^r	Sprenger, unpublished
	pZY557tkttal	<i>E. coli tktA and talB genes in pZY557</i>	This patent application

Strains and plasmids	Genotype/ characteristics	Source or reference
pACYC184	Cm ^r , Tet ^r	Chang and Cohen, J. Bacteriol. 134 (1978) 1141- 1156
pDIA3206	Ap ^r , 11.5 kb insert from <i>E. coli</i> K12 chromosome including <i>ptsHI</i> - <i>crr</i> genes	DeReuse et al., J. Bacteriol. 170 (1988) 3827- 37
pPTS1	pACYC184 containing a 4 kb <i>Cla</i> I fragment which contains the <i>ptsHI</i> and <i>crr</i> genes from pDIA3206; Cm ^r	Jahreis, Osnabruck university, unpublished
pGP704	Amp ^r	Miller et al., J. Bacteriol. 170 (1988) 2575- 83

Table 2

Microorganism	Time after induction/ h	Transaldolase activity/ U · (mg of protein) ⁻¹	
		without induction	with induction
<i>E. coli</i> AT2471/	0		0.64
<i>E. coli</i> AT2471/ pZY557	0 3		0.65 0.80
<i>E. coli</i> AT2471/ pZY557tal	0 3	0.53 0.6	0.61 1.06
<i>E. coli</i> AT2471/ pZY557tkttal	0 3	0.70 0.45	0.80 1.16

C L A I M S

1. Process for the microbial preparation of substances
in which the activity of a transaldolase is increased
5 in a microorganism which is producing these
substances, with the activity of a
phosphoenolpyruvate (PEP)-dependent sugar-uptake
system in this microorganism being present, reduced
or absent.
- 10 2. Process according to Claim 1, characterized in that
the preparation of substances is effected in
microorganisms which have not, prior to the
increasing of the transaldolase activity, been
selected as strains with a switched-off
15 phosphotransferase system (pts⁻ strains) from strains
which previously harboured a phosphotransferase
system (pts⁺ strains).
3. Process according to Claim 1 or 2, characterized in
that substances are prepared in whose synthesis at
20 least one intermediate of the pentose phosphate
pathway is involved.
4. Process according to Claim 3, characterized in that
the intermediate is erythrose 4-phosphate (Ery4P).
5. Process according to Claim 1 or 4, characterized in
25 that the activity of an *Escherichia coli*
transaldolase is increased.
6. Process according to one of Claims 1 to 5,
characterized in that the activity of *Escherichia*
coli transaldolase B (TalB) is increased.
- 30 7. Process according to one of Claims 1 to 6,
characterized in that the activity of a transketolase
is additionally increased.
8. Process according to Claim 7, characterized in that
the activity of an *Escherichia coli* transketolase is

increased.

9. Process according to one of Claims 7 or 8, characterized in that the activity of *Escherichia coli* transketolase A (TktA) is increased.
- 5 10. Process according to one of Claims 1 to 9, characterized in that the activity of a transport protein for the PEP-independent uptake of a sugar and/or the activity of a kinase which phosphorylates the relevant sugar are/is additionally increased.
- 10 11. Process according to Claim 10, characterized in that the transport protein is a facilitator.
12. Process according to Claim 11, characterized in that the facilitator is the *Zymomonas mobilis* glucose facilitator protein (Glf).
- 15 13. Process according to one of Claims 10 to 12, characterized in that the kinase is a hexose-phosphorylating kinase.
14. Process according to Claim 13, characterized in that the kinase is derived from *Zymomonas mobilis*.
- 20 15. Process according to Claim 14, characterized in that the kinase is *Zymomonas mobilis* glucokinase (Glk).
16. Process according to one of Claims 10 to 15, characterized in that the activity of a PEP-dependent sugar uptake system, if present, is additionally
- 25 decreased or switched off.
17. Process according to one of Claims 1 to 16, characterized in that the activity of at least one of the following components, i.e. transaldolase, transketolase, transport protein and kinase, is
- 30 increased
 - a) by introduction of the genes
 - b) and/or by increasing the gene copy number
 - c) and/or by increasing gene expression
 - d) and/or by increasing the endogenous activity of

the said enzymes

- e) and/or by altering the structure of the enzymes
 - f) and/or by using deregulated enzymes
 - g) and/or by inserting genes which encode
- 5 deregulated enzymes.

18. Process according to Claim 17, characterized in that the increase in the activity is achieved by integrating the gene or the genes into a gene structure or into several gene structures, with the gene or the

10 genes being introduced into the gene structure as (a) single copy(ies) or in increased copy number.

19. Process according to one of Claims 1 to 18, characterized in that a microorganism is employed in which one or more enzymes, which are additionally

15 involved in the synthesis of the substances, are deregulated and/or exhibit increased activity.

20. Process according to Claims 1 to 19, characterized in that the substance which is prepared is an aromatic amino acid.

20 21. Process according to Claim 20, characterized in that the aromatic amino acid is L-phenylalanine.

22. Process according to one of Claims 1 to 21, characterized in that the microorganism employed belongs to the genus *Escherichia*, *Serratia*, *Bacillus*,

25 *Corynebacterium* or *Brevibacterium*.

23. Process according to Claim 22, characterized in that the microorganism is *Escherichia coli*.

24. Gene structure containing, in recombinant form,

- a) a gene encoding a transaldolase or a gene

30 encoding a transaldolase and a gene encoding a transketolase, and

- b) at least one gene encoding a transport protein for the PEP-independent uptake of a sugar or encoding a sugar-phosphorylating kinase.

25. Gene structure according to Claim 24, characterized in that the gene for the transport protein encodes a facilitator and the gene for the kinase encodes a hexose-phosphorylating kinase.
- 5 26. Gene structure according to Claim 24 or 25, characterized in that the genes for the transaldolase and the transketolase are derived from *Escherichia coli* and the genes for the transport protein and the kinase are derived from *Zymomonas mobilis*.
- 10 27. Gene structure according to Claims 24 to 26, characterized in that the gene for the *Escherichia coli* transaldolase is *talB* and the gene for the *Escherichia coli* transketolase is *tktA*, and the gene for the *Zymomonas mobilis* transport protein is *glf* and the gene for the *Zymomonas mobilis* kinase is *glk*.
- 15 28. Gene structure according to one of Claims 24 to 27, characterized in that the gene structure contains at least one regulatory gene sequence which is assigned to one of the genes.
- 20 29. Gene structure according to Claim 28, characterized in that at least one of the genes in the gene structure is incorporated such that it is under the control of an inducible promoter.
30. Transformed cell, harbouring, in replicable form, a gene structure according to Claims 24 to 29.
- 25 31. Transformed cell according to Claim 30, characterized in that, in the cell, one or more enzymes which are additionally involved in the synthesis of the substances are deregulated and/or exhibit increased activity.
- 30 32. Transformed cell according to Claim 30 or 31, characterized in that the cell is an *Escherichia coli* cell.
33. Transformed cell according to one of Claims 30 to 32,

characterized in that the activity of the PEP-dependent sugar uptake system, if this system is present, is decreased or switched off.

34. Transformed cell according to one of Claims 30 to 33,
5 characterized in that it is able to produce an aromatic amino acid.

35. Transformed cell according to Claim 34, characterized in that the aromatic amino acid is L-phenylalanine.

36. Process for the microbial preparation of substances
10 according to one of Claims 1 to 23, characterized in that transformed cells according to one of Claims 30 to 35, in which there is a gene structure according to Claim 29, are cultured, with the induction being effected after 2 cell divisions at the earliest.

15 37. Process according to Claim 36, characterized in that, in addition to the intermediates of the pentose phosphate pathway, the transformed cell also contains other metabolites of central metabolism in increased availability.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NL 97/00582

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/54 C12P13/22 C12P19/02 C12P1/00 C12N15/31
C07H11/04 C12N1/21 //C12Q1/48, (C12N1/21, C12R1:07, 1:13,
1:15, 1:185, 1:19, 1:425)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12P C07K C07H C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIAO J.C. ET AL.: "Pathway analysis, engineering, and physiological considerations for redirecting central metabolism" BIOTECHNOLOGY AND BIOENGINEERING, vol. 52, no. 1, 5 October 1996, pages 129-140, XP002053640 cited in the application	1-4, 7-9, 17-23
Y	see abstract see page 130, right-hand column, paragraph 4 see page 132 - page 133 ---	5, 6, 10-16, 24-37
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 February 1998

Date of mailing of the international search report

20/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 97/00582

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FROST J.W. AND DRATHS K.M.: "Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds" ANNUAL REVIEW OF MICROBIOLOGY, vol. 49, 1995, pages 557-579, XP002053641 see page 561 - page 564 ----	1-37
Y	SPRENGER G.A. ET AL.: "Transaldolase B of Escherichia coli K-12: cloning of its gene, talB, and characterization of the enzyme from recombinant strains" JOURNAL OF BACTERIOLOGY, vol. 177, no. 20, October 1995, pages 5930-5936, XP002053305 cited in the application see page 5930, left-hand column, line 1-18 see page 5934, left-hand column; table 2 see page 5935, right-hand column, line 8-21 ----	1-37
P,X	LU J.-L. AND LIAO J.C.: "Metabolic engineering and control analysis for production of aromatics: role of transaldolase" BIOTECHNOLOGY AND BIOENGINEERING, vol. 53, no. 2, 20 January 1997, pages 132-138, XP002053307 see abstract ----	1-9, 17-23
E	WO 96 34961 A (GENENCOR INT ; UNIV MEXICO (MX)) 7 November 1996 cited in the application see abstract see page 1, paragraph 4 - page 4, paragraph 1 ----	1,3,4, 7-10, 16-23
X	ZHANG M. ET AL.: "METABOLIC ENGINEERING OF A PENTOSE METABOLISM PATHWAY IN ETHANOLOGENIC ZYMOONAS MOBILIS" SCIENCE, vol. 267, 13 January 1995, pages 240-243, XP002026045 see page 241 - page 242 ----- -/--	1,3-10, 17-19, 24, 28-31, 33,36,37

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/NL 97/00582

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WALFRIDSSON M. ET AL.: "Xylose-metabolizing Saccharomyces cerevisiae strains overexpressing the tk11 and tal1 genes encoding the pentose phosphate pathway enzymes transketolase and transaldolase" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 61, no. 12, December 1995, pages 4184-4190, XP002053306 see page 4185, left-hand column; figure 1 see page 4188, right-hand column, line 14 - page 4189, left-hand column, line 2</p>	1,3,4,7, 17-19
A	<p>BERRY A.: "Improving production of aromatic compounds in Escherichia coli by metabolic engineering" TRENDS IN BIOTECHNOLOGY, vol. 14, no. 7, July 1996, page 250-256 XP004035764 see page 252, right-hand column, paragraph 2 - page 255, right-hand column, paragraph 1</p>	1-10,13, 15-37
A	<p>GOSSET G. ET AL.: "A direct comparison of approaches for increasing carbon flow to aromatic biosynthesis in Escherichia coli" JOURNAL OF INDUSTRIAL MICROBIOLOGY, vol. 17, no. 1, July 1996, pages 47-52, XP002054313 see abstract see page 50; table 2</p>	1,2
A	<p>WEISSER P. ET AL.: "Functional expression of the glucose transporter of Zymomonas mobilis leads to restoration of glucose and fructose uptake in Escherichia coli mutants and provides evidence for its facilitator action" JOURNAL OF BACTERIOLOGY, vol. 177, no. 11, June 1995, pages 3351-3354, XP002053706 cited in the application</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 97/00582

Patent document
cited in search report

Publication
date

Patent family
member(s)

Publication
date

WO 9634961 A

07-11-96

NONE